<?xml version='1.0' encoding='utf-8'?>
<document id="28224612"><sentence text="Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study." /><sentence text="Paclitaxel is mainly eliminated by CYP2C8 in the liver"><entity charOffset="0-10" id="DDI-PubMed.28224612.s2.e0" text="Paclitaxel" /></sentence><sentence text=" CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide"><entity charOffset="60-80" id="DDI-PubMed.28224612.s3.e0" text="acyl-β-D-glucuronide" /></sentence><sentence text=" To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register"><entity charOffset="97-108" id="DDI-PubMed.28224612.s4.e0" text="clopidogrel" /><entity charOffset="113-123" id="DDI-PubMed.28224612.s4.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.28224612.s4.e0" e2="DDI-PubMed.28224612.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28224612.s4.e0" e2="DDI-PubMed.28224612.s4.e1" /></sentence><sentence text=" Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age- and sex-matched controls treated with paclitaxel and low-dose aspirin"><entity charOffset="151-161" id="DDI-PubMed.28224612.s5.e0" text="paclitaxel" /><entity charOffset="175-182" id="DDI-PubMed.28224612.s5.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.28224612.s5.e0" e2="DDI-PubMed.28224612.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28224612.s5.e0" e2="DDI-PubMed.28224612.s5.e1" /></sentence><sentence text=" By a cumulative dose of 1,500 mg paclitaxel, 35% of the patients had developed severe neuropathy"><entity charOffset="34-44" id="DDI-PubMed.28224612.s6.e0" text="paclitaxel" /></sentence><sentence text=" The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1"><entity charOffset="34-45" id="DDI-PubMed.28224612.s7.e0" text="clopidogrel" /><entity charOffset="61-71" id="DDI-PubMed.28224612.s7.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.28224612.s7.e0" e2="DDI-PubMed.28224612.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28224612.s7.e0" e2="DDI-PubMed.28224612.s7.e1" /></sentence><sentence text="7 (95% confidence interval, 0" /><sentence text="9-3" /><sentence text="0)" /><sentence text=" Among those receiving a high-dose paclitaxel regimen, the hazard ratio was 2"><entity charOffset="35-45" id="DDI-PubMed.28224612.s11.e0" text="paclitaxel" /></sentence><sentence text="3 (95% confidence interval, 1" /><sentence text="1-4" /><sentence text="5)" /><sentence text=" Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high-dose paclitaxel"><entity charOffset="26-37" id="DDI-PubMed.28224612.s15.e0" text="clopidogrel" /><entity charOffset="143-153" id="DDI-PubMed.28224612.s15.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.28224612.s15.e0" e2="DDI-PubMed.28224612.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28224612.s15.e0" e2="DDI-PubMed.28224612.s15.e1" /></sentence><sentence text="" /></document>